Eli Lilly has partnered with Hims & Hers to make its obesity medications, Zepbound and Foundayo, accessible through the Hims & Hers telehealth platform. This move aims to broaden patient access and potentially increase sales for Lilly's key growth drivers, while also boosting Hims & Hers' telehealth offerings.
Eli Lilly announced a strategic partnership with Hims & Hers to distribute its blockbuster obesity drugs, Zepbound and Foundayo, through the telehealth platform. This is a significant move for Lilly as it seeks to maximize the reach and sales of its highly anticipated obesity portfolio, addressing patient access and affordability concerns. For Hims & Hers, integrating these in-demand medications strengthens its position in the telehealth market, potentially attracting new users and increasing revenue. In the short term, this could lead to increased prescription volumes for Lilly and a boost in subscriber numbers for Hims & Hers. Long-term, it solidifies Lilly's distribution strategy and Hims & Hers' role in chronic disease management via telehealth, posing a potential opportunity for traders betting on the continued growth of the obesity drug market and telehealth services.